Tatva Chintan Pharma Peer Comparison

Snapshot Summary

Tatva Chintan Pharma Chem Ltd. stands out as a sector laggard due to its weak growth metrics and high valuation ratios relative to its peers. The company exhibits declining revenue and EPS, alongside high PE and PEG ratios, suggesting it is overvalued given its performance. In contrast, peers like Pidilite Industries and SRF show strong growth and profitability, indicating a more favorable investment profile.

• Tatva Chintan shows negative revenue growth, -2.74% YoY, and declining EPS over 3 years.
• High PE ratio of 622.20 indicates overvaluation, with peers averaging significantly lower values.
• Strong performers like Pidilite Industries and SRF demonstrate solid revenue growth and lower valuation metrics.

• Pidilite Industries Ltd.: Strong revenue growth of 6.12% YoY and a reasonable PE ratio of 76.64.
• SRF Ltd.: Consistent revenue growth of 11.83% YoY and a low PE ratio of 60.69.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
TATVA	₹1,412.70	₹3,302.37Cr	186.20	0.77%	1.19%	0.05
PIDILITIND	₹1,460.50	₹1,48,611.69Cr	66.75	23.21%	31.16%	0.02
SOLARINDS	₹14,161.00	₹1,28,112.65Cr	101.54	29.59%	31.03%	0.33
SRF	₹2,968.10	₹87,981.85Cr	54.39	12.27%	12.83%	0.43
FLUOROCHEM	₹3,728.30	₹40,862.55Cr	65.70	8.31%	10.02%	0.28
GODREJIND	₹1,128.40	₹37,194.85Cr	36.90	20.50%	10.16%	3.73
NAVINFLUOR	₹5,905.50	₹30,238.26Cr	68.09	11.62%	11.76%	0.55

Explore

Watchlists

Command Palette

Tatva Chintan Pharma Peer Comparison

Snapshot Summary